glp 1 agonist uses Another milestone in the evolution of GLP-1-based diabetes therapies glp-1_analogs [TUSOM | Pharmwiki]

Pathophysiologic and therapeutic implications

Evidence from dual-energy X-ray absorptiometry and MRI sub-studies suggests that 2545% of total weight loss with semaglutide and tirzepatide may come from reductions in lean body mass

Current US prescribing information lists personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and previous serious hypersensitivity to tirzepatide or its ingredients as strict contraindications

however, there is no mention of the practical application of the use of these medications beyond the purpose of decreasing GI symptoms in the perioperative setting

This made him hesitant about the clinical value of creating antagonists to histamine, compounds able to block the hormone's action

48 Similarly, among obese individuals without diabetes, semaglutide use was shown to increase the risk of developing GI adverse events by 1.59 times compared with the control group